Orexo

Press release not found

The requested press release could not be found.

No press release identifier was provided.

IR & Corporate Communications Director

Lena Wange

+46 (0)73 064 16 36

ir@orexo.com

Våra senaste pressmeddelanden

Invitation & Agenda: Orexo R&D Day on March 24

6 March 2026 at 10:00

Invitation & Agenda: Orexo R&D Day on March 24

Orexo changes the organizational structure and management team to increase focus on development of new products

6 March 2026 at 08:00

Orexo changes the organizational structure and management team to increase focus on development of new products

Orexo calls for early redemption of its outstanding senior secured social bonds 2024/2028

4 March 2026 at 08:00

Orexo calls for early redemption of its outstanding senior secured social bonds 2024/2028

Orexo: Conversion of Class C shares into ordinary shares and conveyance of ordinary shares within the framework of long-term performance-based incentive programs

19 February 2026 at 17:30 – Regulatory

Orexo: Conversion of Class C shares into ordinary shares and conveyance of ordinary shares within the framework of long-term performance-based incentive programs

Orexo Interim Report Q4 2025, incl. Full Year Report

5 February 2026 at 07:00 – Regulatory – Report – Q4

Orexo Interim Report Q4 2025, incl. Full Year Report

Save the date: Orexo to host R&D Day on March 24

4 February 2026 at 09:30

Save the date: Orexo to host R&D Day on March 24

Orexo invites to a presentation of the Full Year Report 2025

23 January 2026 at 10:30

Orexo invites to a presentation of the Full Year Report 2025

Orexo closes transaction with Dexcel Pharma USA acquiring full rights to Zubsolv in the US

31 December 2025 at 17:00

Orexo closes transaction with Dexcel Pharma USA acquiring full rights to Zubsolv in the US